Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Richard Haugland who wrote (450)	9/28/1998 12:47:00 AM
From: Richard Haugland	Read Replies (1) \| Respond to of 783

Phase III Results Suggest Potent Antiviral Activity for Vertex and Glaxo Wellcome's Second-Generation HIV Protease Inhibitor Agenerase biz.yahoo.com (Note: Epivir = 3TC is a BCHE product) Clinical investigators today presented Phase III clinical trial data for the HIV protease inhibitor Agenerase(R)(amprenavir) which suggest that the drug may be potent and generally well-tolerated in combination with Epivir(R) (lamivudine) also known as 3TC(R), and Retrovir(R) (zidovudine; AZT). These data, presented at a late-breaker slide session at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)support the role of Agenerase in front-line combination antiretroviral therapy. An as-treated analysis of interim 16 week data showed that 88% of patients taking triple therapy with Agenerase+Epivir+Retrovir achieved viral load below the limit of detection of standard assays (<400 copies/mL),compared to 19% of patients taking Epivir+Retrovir alone. An additional analysis showed that 59% of patients receiving this regimen achieved viral load below the limit of detection of an investigational ultrasensitive assay1 (<50 copies). An as-treated analysis evaluates only those patients who remain on study medication through the entire study period.